SCHEMBL30714738

SCHEMBL30714738

Cn1nc2ccc(OCC(F)F)cc2c1C(=O)NC(C)(CO)C(N)=O

nearest known ligand 0.34

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 1/20 0.34
ABHD6 Q9BV23 1/20 0.34
ACACB O00763 2/20 0.34
ALDH1A1 P00352 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
HPGD P15428 1/20 0.33
CYP2C19 P33261 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
KDM4C Q9H3R0 1/20 0.33
PDK1 Q15118 1/20 0.32
PDK2 Q15119 1/20 0.32
CNR2 P34972 5/20 0.32
CNR1 P21554 1/20 0.32
PTGES O14684 2/20 0.32
SYK P43405 1/20 0.31
ADRB1 P08588 2/20 0.31
PTGER4 P35408 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30714639 0.86 KDM4E (0.38) ALDH1A1CYP1A2HPGDSMN1; SMN2KDM4C
SCHEMBL30714609 0.84 OPRL1 (0.34) ALDH1A1CYP1A2CYP2D6CYP2C9HPGD
SCHEMBL30714556 0.83 PARP15 (0.42) SMN1; SMN2
SCHEMBL30714580 0.83 CYP11B2 (0.37) ALDH1A1CYP1A2CYP2D6CYP2C9HPGD
SCHEMBL30714624 0.83 CNR2 (0.40) CNR2
SCHEMBL30714690 0.83 ALOX5AP (0.40)
SCHEMBL30714640 0.82 CNR2 (0.36) CNR2
SCHEMBL30714591 0.82 PARP10 (0.41) CYP2C9CYP2C19
SCHEMBL31539882 0.81 ACACB (0.38) MGLLABHD6ACACBALDH1A1CYP1A2
SCHEMBL30714551 0.81 ALOX5AP (0.39) CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-12-11 US disclosed
EP-4499624-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-02-05 EP disclosed
WO-2023230540-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS TRPV3, TRPM2, TRPV1 MGLL 1105/4885ABHD6 3756/4885ACACB 2553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.